Using network-based methods to find new drug options for Alzheimer's disease
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimers Disease
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10769866
This study is looking for new ways to use existing medications to help people with Alzheimer's by understanding the genetic factors that contribute to the disease, which could lead to better treatment options that are personalized for each patient.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10769866 on ClinicalTrials.gov |
What this research studies
This research investigates innovative approaches to drug repurposing for Alzheimer's disease by focusing on complex genetic factors and shared disease mechanisms. It aims to identify underlying endophenotypes, such as amyloidosis and tauopathy, that are common across various neurodegenerative diseases. By integrating data from multiple biological layers, including the genome and proteome, the study seeks to uncover new targets for treatment that could lead to more effective therapies for Alzheimer's. Patients may benefit from potential new drug options that are tailored to their specific genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk due to genetic factors.
Not a fit: Patients with Alzheimer's disease caused by non-genetic factors or those with advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for Alzheimer's disease, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using network-based approaches for drug discovery in other complex diseases, suggesting potential success in this novel application for Alzheimer's.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHENG, FEIXIONG — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: CHENG, FEIXIONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease